NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.<\/p>
Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement\u2019s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL16998"} , {"_value" : "HL16999"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-15T10:23:54.303Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2168", "label" : {"_value" : "Biography information for Baroness Morgan of Huyton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Morgan of Huyton"} ], "uin" : "HL16997"} , {"_about" : "http://data.parliament.uk/resources/1137391", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1137391/answer", "answerText" : {"_value" : "
NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.<\/p>
Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement\u2019s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL16997"} , {"_value" : "HL16999"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-15T10:23:54.243Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2168", "label" : {"_value" : "Biography information for Baroness Morgan of Huyton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Morgan of Huyton"} ], "uin" : "HL16998"} , {"_about" : "http://data.parliament.uk/resources/1137392", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1137392/answer", "answerText" : {"_value" : "
NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.<\/p>
Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement\u2019s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL16997"} , {"_value" : "HL16998"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-15T10:23:54.35Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2168", "label" : {"_value" : "Biography information for Baroness Morgan of Huyton"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Morgan of Huyton"} ], "uin" : "HL16999"} , {"_about" : "http://data.parliament.uk/resources/1137406", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1137406/answer", "answerText" : {"_value" : "
As outlined in both the NHS Long Term Plan and Investment and evolution: a five-year framework for GP contract reform to implement The NHS Long Term Plan<\/em>, NHS England and NHS Improvement are currently undertaking a Review of vaccinations and immunisations. The Department would not wish to pre-empt the outcome of this Review. Investment and evolution<\/em> sets out the purpose of the Review as being to:<\/p> - Ensure the system incentivises achievement of appropriate uptake rates for immunisations in line with national public health uptake rates;<\/p> - Reduce the administrative burden on general practices by simplifying the system if possible;<\/p> - Clarify what is expected on call/recall for immunisations delivered through the general practitioner (GP) contract;<\/p> - Address anomalies in the system that directly incentivise some vaccines but not others;<\/p> - Look at how we deal with outbreaks and catch-up programmes; and<\/p> - Consider whether we extend the list of chargeable travel vaccines.<\/p> Recommendations from the Review will be implemented through the 2020 and 2021 GP contracts.<\/p> A copy of Investment and evolution: a five-year framework for GP contract reform to implement The NHS Long Term Plan<\/em> is attached.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
}
, "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/1137406/answer/attachment/1", "fileName" : {"_value" : "gp-contract-2019.pdf"}
, "title" : "Five Year framework for GP contract reform"}
, "dateOfAnswer" : {"_value" : "2019-07-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-19T09:14:02.963Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Shingles: Vaccination"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what plans they have to establish a GP-operated call/recall system to invite older people to receive the shingles vaccination.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2547", "label" : {"_value" : "Biography information for Baroness Walmsley"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Walmsley"}
], "uin" : "HL17013"}
, {"_about" : "http://data.parliament.uk/resources/1137409", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1137409/answer", "answerText" : {"_value" : " The Department collaborated with the Royal College of Physicians on the National Review of Asthma Deaths and welcomed this report. Since its publication, significant improvements have been made in asthma care.<\/p> <\/p> Respiratory disease, including asthma, is a clinical priority within the NHS Long Term Plan, which aims to improve outcomes for patients through earlier diagnosis and increased access to treatments. The Respiratory Delivery Board will take forward respiratory proposals set out in the Plan by working with key partners.<\/p> <\/p> The National Health Service is supporting the national asthma audit programme which provides data on a range of indicators to show improvements and opportunities in asthma outcomes. NHS RightCare will be publishing an asthma toolkit later this year to support local commissioners and systems in delivering quality care. A best practice tariff for asthma, which aims to reduce variation in asthma care, is also in development.<\/p> <\/p> The current quality outcomes framework indicators for asthma are in consultation and changes for the annual review indicators may include data on asthma control; exacerbations; and written personalised action plans.<\/p> <\/p> As set out in the Long Term Plan, pharmacies in primary care networks will undertake medicine reviews for asthma patients. This will include education on inhaler use and uptake of dry powder and smart inhalers where clinically appropriate.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
}
, "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
, "dateOfAnswer" : {"_value" : "2019-07-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-19T09:14:58.157Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Death"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what assessment they have made of the report by the Royal College of Physicians The National Review of Asthma Deaths, published on 6 May 2014; and what plans they have to implement that report's recommendations.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4157", "label" : {"_value" : "Biography information for Baroness Wheeler"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Wheeler"}
], "uin" : "HL17016"}
, {"_about" : "http://data.parliament.uk/resources/1137416", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1137416/answer", "answerText" : {"_value" : " In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.<\/p> The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.<\/p> The AAC will consider the following areas of interest when determining which products to support:<\/p> - evidence of clinical and cost effectiveness;<\/p> - addressing significant unmet need;<\/p> - application to large populations or high budget impact; and<\/p> - enabling a novel mode of action or enabling significant changes to the care pathway.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-15T15:23:36.753Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Accelerated Access Collaborative"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will list (a) the criteria and (b) the timelines for products to be considered in (i) the current and (ii) future review rounds of the Accelerated Access Collaborative.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "274540"}
, {"_about" : "http://data.parliament.uk/resources/1137417", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1137417/answer", "answerText" : {"_value" : " The Accelerated Access Collaborative (AAC) is interested in identifying and supporting strategically important products that will have the biggest impact on patient health outcomes and/or the delivery of National Health Service services. This may include those which help control hospital-acquired infections.<\/p> The AAC has already had made significant progress towards getting the best innovations to patients quicker and at a better cost for the NHS.<\/p> Since 2018, NHS England has been supporting SecurAcath and Plus Sutures, products designed to reduce infection rates, on the Innovation and Technology Payment programme. SecurAcath is a device to secure catheters that reduces the infection risk for patients with a peripherally inserted central catheter and has benefited over 80,000 patients. Seven trusts with higher than 4% surgical site infection rates have adopted Plus Sutures, a triclosan coated suture, with more trusts to be supported this year.<\/p> <\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-15T15:26:22.27Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hospitals: Infectious Diseases"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans the Accelerated Access Collaborative has to prioritise products which help to control hospital-acquired infections.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "274541"}
, {"_about" : "http://data.parliament.uk/resources/1137418", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1137418/answer", "answerText" : {"_value" : " The Accelerated Access Collaborative (AAC) is interested in supporting the most strategically important products that will have the biggest impact on patient health outcomes and delivery of National Health Service services.<\/p> When selecting products, the AAC will consider the following irrespective of innovation type (i.e. medicines, diagnostic tools, and digital products):<\/p> - evidence of clinical and cost effectiveness;<\/p> - addressing significant unmet need;<\/p> - application to large populations or high budget impact; and<\/p> - enabling a novel mode of action or enabling significant changes to the care pathway.<\/p> Further information is available at the following link:<\/p> https://www.nice.org.uk/aac<\/a><\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-15T15:33:03.587Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Accelerated Access Collaborative"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what criteria the Accelerated Access Collaborative uses in relation to decision-making on (a) medicines, (b) diagnostic tools and (c) digital services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "274542"}
, {"_about" : "http://data.parliament.uk/resources/1137423", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1137423/answer", "answerText" : {"_value" : " Following agreement with the Department and industry as part of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (voluntary scheme), the National Institute for Health and Care Excellence (NICE) is now expected to undertake appropriate appraisal for all new active substances in their first indication, and extensions to their Marketing Authorisation to add a significant new therapeutic indication, except where there is a clear rationale not to do so. NICE expects to implement this expansion from April 2020. They will be in a position to start progressing topics through the NICE topic selection process from the summer of 2019.<\/p> The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme instead.<\/p> Furthermore, NHS England advises that all policy propositions that were previously being developed by the Commissioning Support Programme have been handed over to the relevant committee, to bring them in line with the usual development process. This process is set out in \u2018Methods: National Clinical Policies\u2019 at the following link:<\/p>